Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Jan;6(1):141–151. doi: 10.1016/j.nurt.2008.10.035

Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

Jacobus P Petzer 1,✉, Neal Castagnoli 2, Michael A Schwarzschild 3, Jiang -Fan Chen 4, Cornelis J Van der Schyf 5
PMCID: PMC5084262  PMID: 19110205

Summary

Inadequacies of the current pharmacotherapies to treat Parkinson’s disease (PD) have prompted efforts to identify novel drug targets. The adenosine A2A receptor is one such target. Antagonists of this receptor (A2A antagonists) are considered promising agents for the symptomatic treatment of PD. Evidence suggests that A2A antagonists may also have neuroprotective properties that may prevent the development of the dyskinesia that often complicates levodopa treatment. Because the therapeutic benefits of A2A antagonists are additive to that of dopamine replacement therapy, it may be possible to reduce the dose of the dopaminergic drugs and therefore the occurrence of side effects. Inhibitors of monoamine oxidase (MAO)-B also are considered useful tools for the treatment of PD. When used in combination with levodopa, inhibitors of MAO-B may enhance the elevation of dopamine levels after levodopa treatment, particularly when used in early stages of the disease when dopamine production may not be so severely compromised. Furthermore, MAO-B inhibitors may also possess neuroprotective properties in part by reducing the damaging effect of dopamine turnover in the brain. These effects of MAO-B inhibitors are especially relevant when considering that the brain shows an age-related increase in MAO-B activity. Based on these observations, dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A2A receptors, may have value in the management of PD. This review summarizes recent efforts to develop such dual-acting drugs using caffeine as the lead compound.

Key Words: Parkinson’s disease, monoamine oxidase B, adenosine A2A receptor, dual-target-directed drug, caffeine

References

  • 1.Allain H, Bentué-Ferrer D, Akwa Y. Disease-modifying drugs and Parkinson’s disease. Prog Neurobiol. 2008;84:25–39. doi: 10.1016/j.pneurobio.2007.10.003. [DOI] [PubMed] [Google Scholar]
  • 2.Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/s0896-6273(03)00568-3. [DOI] [PubMed] [Google Scholar]
  • 3.Lew M. Overview of Parkinson’s disease. Pharmacotherapy. 2007;27:155S–160S. doi: 10.1592/phco.27.12part2.155S. [DOI] [PubMed] [Google Scholar]
  • 4.Voss T, Ravina B. Neuroprotection in Parkinson’s disease: myth or reality? Curr Neurol Neurosci Rep. 2008;8:304–309. doi: 10.1007/s11910-008-0047-5. [DOI] [PubMed] [Google Scholar]
  • 5.Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy. 2007;27:161S–173S. doi: 10.1592/phco.27.12part2.161S. [DOI] [PubMed] [Google Scholar]
  • 6.Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21:677–692. doi: 10.2165/00023210-200721080-00005. [DOI] [PubMed] [Google Scholar]
  • 7.Rezak M. Current pharmacotherapeutic treatment options in Parkinson’s disease. Dis Mon. 2007;53:214–222. doi: 10.1016/j.disamonth.2007.05.002. [DOI] [PubMed] [Google Scholar]
  • 8.Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs Aging. 2005;22:731–740. doi: 10.2165/00002512-200522090-00002. [DOI] [PubMed] [Google Scholar]
  • 9.Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27:174S–185S. doi: 10.1592/phco.27.12part2.174S. [DOI] [PubMed] [Google Scholar]
  • 10.Youdim MB, Collins GG, Sandler M, Bevan Jones AB, Pare CM, Nicholson WJ. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature. 1972;236:225–228. doi: 10.1038/236225b0. [DOI] [PubMed] [Google Scholar]
  • 11.Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain mitochondrial monoamine oxidase. Nature. 1970;225:817–820. doi: 10.1038/225817a0. [DOI] [PubMed] [Google Scholar]
  • 12.Di Monte DA, DeLanney LE, Irwin I, et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res. 1996;738:53–59. doi: 10.1016/0006-8993(96)00761-5. [DOI] [PubMed] [Google Scholar]
  • 13.Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl. 1998;52:279–285. doi: 10.1007/978-3-7091-6499-0_28. [DOI] [PubMed] [Google Scholar]
  • 14.Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol. 2006;147:S287–S296. doi: 10.1038/sj.bjp.0706464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nicotra A, Pierucci F, Parvez H, Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology. 2004;25:155–165. doi: 10.1016/S0161-813X(03)00095-0. [DOI] [PubMed] [Google Scholar]
  • 16.Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–435. doi: 10.1016/s0197-4580(97)00037-7. [DOI] [PubMed] [Google Scholar]
  • 17.Karolewicz B, Klimek V, Zhu H, et al. Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. Brain Res. 2005;1043:57–64. doi: 10.1016/j.brainres.2005.02.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm. 1980;49:1–20. doi: 10.1007/BF01249185. [DOI] [PubMed] [Google Scholar]
  • 19.Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson’s disease. Pharmacol Ther. 2005;105:267–310. doi: 10.1016/j.pharmthera.2004.10.007. [DOI] [PubMed] [Google Scholar]
  • 20.Pinna A, Wardas J, Simola N, Morelli M. New therapies for the treatment of Parkinson’s disease: adenosine A2A receptor antagonists. Life Sci. 2005;77:3259–3267. doi: 10.1016/j.lfs.2005.04.029. [DOI] [PubMed] [Google Scholar]
  • 21.Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and 1-DOPA-induced motor complications. Prog Neurobiol. 2007;83:293–309. doi: 10.1016/j.pneurobio.2007.07.001. [DOI] [PubMed] [Google Scholar]
  • 22.Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 2006;29:647–654. doi: 10.1016/j.tins.2006.09.004. [DOI] [PubMed] [Google Scholar]
  • 23.Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol. 2003;184:285–94. doi: 10.1016/s0014-4886(03)00250-4. [DOI] [PubMed] [Google Scholar]
  • 24.Jacobson KA, Gallo-Rodriguez C, Melman N, et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem. 1993;36:1333–1342. doi: 10.1021/jm00062a005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Müller CE, Geis U, Hipp J, et al. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. J Med Chem. 1997;40:4396–4405. doi: 10.1021/jm970515+. [DOI] [PubMed] [Google Scholar]
  • 26.Chen JF, Steyn S, Staal R, et al. 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem. 2002;277:36040–36044. doi: 10.1074/jbc.M206830200. [DOI] [PubMed] [Google Scholar]
  • 27.Petzer JP, Steyn S, Castagnoli KP, et al. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg Med Chem. 2003;11:1299–1310. doi: 10.1016/s0968-0896(02)00648-x. [DOI] [PubMed] [Google Scholar]
  • 28.Vlok N, Malan SF, Castagnoli N, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC) Bioorg Med Chem. 2006;14:3512–2351. doi: 10.1016/j.bmc.2006.01.011. [DOI] [PubMed] [Google Scholar]
  • 29.Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552. [PMC free article] [PubMed] [Google Scholar]
  • 30.Ishiwata K, Mishina M, Kimura Y, Oda K, Sasaki T, Ishii K. First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse. 2005;55:133–136. doi: 10.1002/syn.20099. [DOI] [PubMed] [Google Scholar]
  • 31.Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol. 1989;168:243–246. doi: 10.1016/0014-2999(89)90571-2. [DOI] [PubMed] [Google Scholar]
  • 32.Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 1991;57:1062–1067. doi: 10.1111/j.1471-4159.1991.tb08257.x. [DOI] [PubMed] [Google Scholar]
  • 33.Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res. 1992;14:186–195. doi: 10.1016/0169-328x(92)90173-9. [DOI] [PubMed] [Google Scholar]
  • 34.Ferré S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 1991;88:7238–7241. doi: 10.1073/pnas.88.16.7238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ferré S, O’Connor WT, Fuxe K, Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci. 1993;13:5402–5406. doi: 10.1523/JNEUROSCI.13-12-05402.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997;20:482–487. doi: 10.1016/s0166-2236(97)01096-5. [DOI] [PubMed] [Google Scholar]
  • 37.Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel anti-Parkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507–513. doi: 10.1002/ana.410430415. [DOI] [PubMed] [Google Scholar]
  • 38.Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice. Proc Natl Acad Sci USA. 2001;98:1970–1975. doi: 10.1073/pnas.98.4.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of 1-DOPA-induced dyskinesia. J Neurochem. 2003;84:1398–1410. doi: 10.1046/j.1471-4159.2003.01632.x. [DOI] [PubMed] [Google Scholar]
  • 40.Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 1997;321:143–147. doi: 10.1016/s0014-2999(96)00944-2. [DOI] [PubMed] [Google Scholar]
  • 41.Jiang H, Jackson-Lewis V, Muthane U, et al. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res. 1993;613:347–351. doi: 10.1016/0006-8993(93)90925-d. [DOI] [PubMed] [Google Scholar]
  • 42.Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H. Anti-Parkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–1677. doi: 10.1212/wnl.52.8.1673. [DOI] [PubMed] [Google Scholar]
  • 43.Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases anti-Parkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321–327. doi: 10.1006/exnr.2000.7350. [DOI] [PubMed] [Google Scholar]
  • 44.Rose S, Jackson MJ, Smith LA, et al. The novel adenosine A2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol. 2006;546:82–87. doi: 10.1016/j.ejphar.2006.07.017. [DOI] [PubMed] [Google Scholar]
  • 45.Popoli P, Reggio R, Pèzzola A, Fuxe K, Ferré S. Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neurosci Lett. 1998;251:201–204. doi: 10.1016/s0304-3940(98)00533-3. [DOI] [PubMed] [Google Scholar]
  • 46.Shimada J, Koike N, Nonaka H, et al. Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett. 1997;18:2349–2352. [Google Scholar]
  • 47.Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A2A receptor antagonist treatment of Parkinson’s disease. Neurology. 2003;61:293–296. doi: 10.1212/01.wnl.0000073136.00548.d4. [DOI] [PubMed] [Google Scholar]
  • 48.Hauser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303. doi: 10.1212/01.wnl.0000081227.84197.0b. [DOI] [PubMed] [Google Scholar]
  • 49.Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology. 2003;61:S107–S111. doi: 10.1212/01.wnl.0000095223.08711.48. [DOI] [PubMed] [Google Scholar]
  • 50.LeWitt PA, Guttman M, Tetrad JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann Neurol. 2008;63:295–302. doi: 10.1002/ana.21315. [DOI] [PubMed] [Google Scholar]
  • 51.Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol. 1998;56:591–611. doi: 10.1016/s0301-0082(98)00053-7. [DOI] [PubMed] [Google Scholar]
  • 52.Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol. 2001;50:56–63. doi: 10.1002/ana.1052. [DOI] [PubMed] [Google Scholar]
  • 53.Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674–2679. doi: 10.1001/jama.283.20.2674. [DOI] [PubMed] [Google Scholar]
  • 54.Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson’s disease risk. Mov Disord. 2008;23:88–95. doi: 10.1002/mds.21782. [DOI] [PubMed] [Google Scholar]
  • 55.Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology. 2003;60:790–795. doi: 10.1212/01.wnl.0000046523.05125.87. [DOI] [PubMed] [Google Scholar]
  • 56.Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 2001;21:RC143–RC143. doi: 10.1523/JNEUROSCI.21-10-j0001.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem. 2002;80:262–270. doi: 10.1046/j.0022-3042.2001.00694.x. [DOI] [PubMed] [Google Scholar]
  • 58.Joghataic MT, Roghani M, Negahdar F, Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson’s disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord. 2004;10:465–468. doi: 10.1016/j.parkreldis.2004.06.004. [DOI] [PubMed] [Google Scholar]
  • 59.Bové J, Senats J, Mengod G, Cortés R, Tolosa E, Marin C. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of Parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res. 2005;165:362–374. doi: 10.1007/s00221-005-2302-1. [DOI] [PubMed] [Google Scholar]
  • 60.Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse. 2001;39:233–238. doi: 10.1002/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 61.Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci. 2002;22:1054–1062. doi: 10.1523/JNEUROSCI.22-03-01054.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Xiao D, Bastia E, Xu YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemi-Parkinsonian mice. J Neurosci. 2006;26:13548–13555. doi: 10.1523/JNEUROSCI.3554-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J. 2001;20:3893–3901. doi: 10.1093/emboj/20.15.3893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Edmondson DE, Binda C, Mattevi A. The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology. 2004;25:63–72. doi: 10.1016/S0161-813X(03)00114-1. [DOI] [PubMed] [Google Scholar]
  • 65.Weyler W, Hsu YP, Breakefield XO. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther. 1990;47:391–417. doi: 10.1016/0163-7258(90)90064-9. [DOI] [PubMed] [Google Scholar]
  • 66.Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197–217. doi: 10.1146/annurev.neuro.22.1.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295–309. doi: 10.1038/nrn1883. [DOI] [PubMed] [Google Scholar]
  • 68.Waldmeier PC. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain) J Neural Transm Suppl. 1987;23:55–72. doi: 10.1007/978-3-7091-8901-6_4. [DOI] [PubMed] [Google Scholar]
  • 69.Inoue H, Castagnoli K, Van Der Schyf C, Mabic S, Igarashi K, Castagnoli N. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther. 1999;291:856–864. [PubMed] [Google Scholar]
  • 70.Weyler W, Salach JI. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem. 1985;260:13199–207. [PubMed] [Google Scholar]
  • 71.Saura J, Nadal E, van den Berg B, Vila M, Bombi JA, Mahy N. Localization of monoamine oxidases in human peripheral tissues. Life Sci. 1996;59:1341–1349. doi: 10.1016/0024-3205(96)00459-6. [DOI] [PubMed] [Google Scholar]
  • 72.Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science. 1985;230:181–183. doi: 10.1126/science.3875898. [DOI] [PubMed] [Google Scholar]
  • 73.Kalaria RN, Mitchell MJ, Harik SI. Monoamine oxidases of the human brain and liver. Brain. 1988;111:1441–1451. doi: 10.1093/brain/111.6.1441. [DOI] [PubMed] [Google Scholar]
  • 74.Willoughby J, Glover V, Sandler M, Albanese A, Jenner P, Marsden CD. Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. Neurosci Lett. 1988;90:100–106. doi: 10.1016/0304-3940(88)90794-x. [DOI] [PubMed] [Google Scholar]
  • 75.Riachi NJ, Harik SI. Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys. Exp Neurol. 1992;115:212–217. doi: 10.1016/0014-4886(92)90055-u. [DOI] [PubMed] [Google Scholar]
  • 76.Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA. 1982;79:6385–6389. doi: 10.1073/pnas.79.20.6385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Fowler JS, Logan J, Volkow ND, Wang GJ, MacGregor RR, Ding YS. Monoamine oxidase: radiotracer development and human studies. Methods. 2002;27:263–277. doi: 10.1016/s1046-2023(02)00083-x. [DOI] [PubMed] [Google Scholar]
  • 78.Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36:303–326. doi: 10.1007/BF01253131. [DOI] [PubMed] [Google Scholar]
  • 79.Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604–612. doi: 10.1002/ana.10191. [DOI] [PubMed] [Google Scholar]
  • 80.Pålhagen S, Heinonen EH, Hägglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 1998;51:520–525. doi: 10.1212/wnl.51.2.520. [DOI] [PubMed] [Google Scholar]
  • 81.Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67:S24–S29. doi: 10.1212/wnl.67.7_suppl_2.s24. [DOI] [PubMed] [Google Scholar]
  • 82.Parkinson Study Group Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol. 1996;40:99–107. doi: 10.1002/ana.410400116. [DOI] [PubMed] [Google Scholar]
  • 83.Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–1206. doi: 10.1212/01.wnl.0000204007.46190.54. [DOI] [PubMed] [Google Scholar]
  • 84.Parkinson study group A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch Neurol. 2004;61:561–566. doi: 10.1001/archneur.61.4.561. [DOI] [PubMed] [Google Scholar]
  • 85.Gesi M, Santinami A, Ruffoli R, Conti G, Fomai F. Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties) Pharmacol Toxicol. 2001;89:217–224. doi: 10.1034/j.1600-0773.2001.d01-151.x. [DOI] [PubMed] [Google Scholar]
  • 86.Fomai F, Giorgi FS, Bassi L, Ferrucci M, Alessandrì MG, Corsini GU. Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res. 2000;861:126–134. doi: 10.1016/s0006-8993(00)02054-0. [DOI] [PubMed] [Google Scholar]
  • 87.Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacet-aldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007;59:125–150. doi: 10.1124/pr.59.2.1. [DOI] [PubMed] [Google Scholar]
  • 88.Götz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson’s disease. J Neural Transm Suppl. 1990;29:241–249. doi: 10.1007/978-3-7091-9050-0_23. [DOI] [PubMed] [Google Scholar]
  • 89.Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515–520. doi: 10.1111/j.1471-4159.1989.tb09150.x. [DOI] [PubMed] [Google Scholar]
  • 90.Grünblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm. 2004;111:1543–1573. doi: 10.1007/s00702-004-0212-1. [DOI] [PubMed] [Google Scholar]
  • 91.Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984;120:574–578. doi: 10.1016/0006-291x(84)91293-2. [DOI] [PubMed] [Google Scholar]
  • 92.Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984;224:1451–1453. doi: 10.1126/science.6610213. [DOI] [PubMed] [Google Scholar]
  • 93.Langsten JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  • 94.Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984;311:467–469. doi: 10.1038/311467a0. [DOI] [PubMed] [Google Scholar]
  • 95.Collins MA, Neafsey EJ. Potential neurotoxic “agents provocateurs” in Parkinson’s disease. Neurotoxicol Teratol. 2002;24:571–577. doi: 10.1016/s0892-0362(02)00210-6. [DOI] [PubMed] [Google Scholar]
  • 96.Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005:379–387. [DOI] [PubMed]
  • 97.Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 2005;41:369–391. doi: 10.1358/dot.2005.41.6.893613. [DOI] [PubMed] [Google Scholar]
  • 98.Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675–682. doi: 10.1016/s0892-0362(02)00221-0. [DOI] [PubMed] [Google Scholar]
  • 99.Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67:577–585. doi: 10.1016/s0024-3205(00)00643-3. [DOI] [PubMed] [Google Scholar]
  • 100.Kitani K, Kanai S, Ivy GO, Carrillo MC. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech Ageing Dev. 1999;111:211–221. doi: 10.1016/s0047-6374(99)00065-2. [DOI] [PubMed] [Google Scholar]
  • 101.Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83–133. [PubMed] [Google Scholar]
  • 102.Baraldi PG, Tabrizi MA, Bovero A, et al. Recent developments in the field of A2A and A3 adenosine receptor antagonists. Eur J Med Chem. 2003;38:367–382. doi: 10.1016/s0223-5234(03)00042-4. [DOI] [PubMed] [Google Scholar]
  • 103.Ongini E, Monopoli A, Cacciari B, Baraldi PG. Selective adenosine A2A receptor antagonists. Farmaco. 2001;56:87–90. doi: 10.1016/s0014-827x(01)01024-2. [DOI] [PubMed] [Google Scholar]
  • 104.Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90–95. doi: 10.1007/s002130051146. [DOI] [PubMed] [Google Scholar]
  • 105.Suzuki F, Shimada J, Shiozaki S, et al. Adenosine A, antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance. J Med Chem. 1993;36:2508–2518. doi: 10.1021/jm00069a009. [DOI] [PubMed] [Google Scholar]
  • 106.Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF 17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256:263–268. doi: 10.1016/0014-2999(94)90551-7. [DOI] [PubMed] [Google Scholar]
  • 107.Del Giudice MR, Borioni S, Mustazza C, et al. (E)-1-(Heterocyclyl or cyclohexyl)-2-[1,3,7-trisubstituted(xanthin-8-yl)]ethenes as A2A adenosine receptor antagonists. Eur J Med Chem. 1996;31:59–63. [Google Scholar]
  • 108.Van den Berg D, Zoellner KR, Ogunrombi MO, et al. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg Med Chem. 2007;15:3692–3702. doi: 10.1016/j.bmc.2007.03.046. [DOI] [PubMed] [Google Scholar]
  • 109.Castagnoli N, Petzer JP, Steyn S, et al. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 2003;61:S62–S68. doi: 10.1212/01.wnl.0000095215.97585.59. [DOI] [PubMed] [Google Scholar]
  • 110.Pretorius J, Malan SF, Castagnoli N, Bergh JJ, Petzer JP. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-l-yl)caffeine analogues. Bioorg Med Chem. 2008;16:8676–8684. doi: 10.1016/j.bmc.2008.07.088. [DOI] [PubMed] [Google Scholar]
  • 111.Binda C, Newton-Vinson P, Hubálek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002;9:22–26. doi: 10.1038/nsb732. [DOI] [PubMed] [Google Scholar]
  • 112.Binda C, Li M, Hubálek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA. 2003;100:9750–9755. doi: 10.1073/pnas.1633804100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Hubálek F, Binda C, Khalil A, et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem. 2005;280:15761–15766. doi: 10.1074/jbc.M500949200. [DOI] [PubMed] [Google Scholar]
  • 114.Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848–5852. doi: 10.1021/jm070677y. [DOI] [PubMed] [Google Scholar]
  • 115.Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J Med Chem. 2007;50:6446–6449. doi: 10.1021/jm701225u. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES